Biogen To Report New Data of its Biosimilar Anti-TNF Portfolio at European Congress of Rheumatology (EULAR) 2019

Biogen Reports New Data of its Biosimilar Anti-TNF Portfolio at European Congress of Rheumatology (EULAR) 2019

Shots:

  • Biogen to present data from BENEFIT study results assessing etanercept in 533 patients with rheumatoid arthritis and axial spondyloarthritis. Additionally, it presents data from pooled analyses of etanercept, infliximab and imraldi in 1,461 patients showing similarity with its reference product @6mos. & @1yr. treatment
  • Biogen’s three biosimilar, Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab) are expected to save $2.04B of European healthcare system in 2019. In Feb’12, Biogen & Samsung Biologics collaborates to develop & commercialize biosimilar
  • Benepali (biosimilar of Enbrel), flixabi (biosimilar of Remicade), imraldi (biosimilar of Humira) received European Commission approval in Jan’16, May’16 and Aug’17 for multiple indication respectively

Click here to read full press release/ article | Ref: Biogen | Image: Bizjournals